comprehensive -WSS

comprehensive

author：hotspot 2025-09-03 14:41:25 - browse：48

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Choosing scientific sides in the fight against Alzheimer's

WSS

Sage's campaign to raise awareness of postpartum depression hits a nerve

Johnson & Johnson sues to stop Medicare negotiation

Discs beat pads, tampons for heavy menstrual flow, new study shows

A Theranos scientist

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

15 die by electrocution after transformer explodes in northern India

hotspot

comprehensive

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

More hospitals are billing patients as online messages surge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Ohioans vote in high

Medicare details structure of new drug price negotiation program

Lessons Learned: This is why you network to find that industry job you want

Medicare proposal to cover medical devices draws a mixed reaction

Discs beat pads, tampons for heavy menstrual flow, new study shows

Anesthesiologist group: stop taking Ozempic before surgery

Sage's campaign to raise awareness of postpartum depression hits a nerve

entertainment

Why you get paid to donate plasma but not blood

Lack of darker skin in textbooks, journals harms patients of color

BridgeBio heart drug succeeds in pivotal study

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Choosing scientific sides in the fight against Alzheimer's

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

knowledge

Wikipedia

hotspot

focus